J. Martinez

发表

Effectiveness of adjunctive antidepressant treatment for bipolar depression.

David J Miklowitz, Joseph R Calabrese, Laszlo Gyulai, 2007, The New England journal of medicine.

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache

C. Gaul, M. Rettiganti, D. Kudrow, 2021, Journal of pain research.

The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.

M. Fava, L. Marangell, J. Greist, 2007, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder: Comparison of Switching Versus Initiating Treatment Approaches

M. Fava, C. Mallinckrodt, J. Martinez, 2005, Journal of clinical psychopharmacology.

Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache

C. Gaul, M. Bangs, J. Martinez, 2022, Cephalalgia : an international journal of headache.

F Do ‘ fish oils ’ have a therapeutic role in psychiatry ?

L. Marangell, J. Martinez, 2004 .

Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review

D. Dodick, P. Goadsby, M. Ashina, 2022, Headache.

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

R. Conley, D. Dodick, S. Aurora, 2020, Cephalalgia : an international journal of headache.

Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BD.

M. Thase, S. Wisniewski, N. Simon, 2005, Psychiatric services.

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine

M. Hodsdon, E. Pearlman, J. Martinez, 2020, Cephalalgia : an international journal of headache.

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial

Kirk W. Johnson, A. Schacht, D. Dodick, 2017, JAMA neurology.

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache

C. Gaul, M. Rettiganti, D. Kudrow, 2020, Headache.

Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.

L. Marangell, H. Zboyan, Christopher R. Johnson, 2002, The Journal of clinical psychiatry.

Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.

S. Ball, P. Liu, C. Goldberger, 2016, The Journal of clinical psychiatry.

Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD.

J. Calabrese, M. Thase, D. Miklowitz, 2004, Bipolar disorders.

Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes.

A. Rush, H. Sackeim, Z. Nahas, 2005, The Journal of clinical psychiatry.

A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression.

L. Marangell, H. Zboyan, J. Martinez, 2003, The American journal of psychiatry.

Prospective predictors of suicide and suicide attempts in 1,556 patients with bipolar disorders followed for up to 2 years.

M. Thase, S. Wisniewski, E. Frank, 2006, Bipolar disorders.

Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder

A. Heinloth, B. Fijal, J. Houston, 2012, Psychiatry Research.

Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study

L. Marangell, D. Hann, M. Robinson, 2011, Current medical research and opinion.

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment

J. Schoenen, M. Láinez, M. Bangs, 2021, Headache.

Clinical Characteristics and Treatment Patterns Among Patients Diagnosed With Cluster Headache in U.S. Healthcare Claims Data

S. Aurora, R. Robinson, A. Nyhuis, 2017, Headache.

Drug, Healthcare and Patient Safety Dovepress

Qi Zhang, M. Bangs, J. Martinez, 2022 .

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis

D. Dodick, S. Aurora, P. Goadsby, 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

Omega‐3 fatty acids for the prevention of postpartum depression: Negative data from a preliminary, open‐label pilot study

L. Marangell, H. Zboyan, J. Martinez, 2004, Depression and anxiety.

Vagus nerve stimulation: current use and potential applications in child and adolescent psychiatry.

L. Marangell, J. Martinez, L. Hollrah, 2005, Child and adolescent psychiatric clinics of North America.

Trial of Galcanezumab in Prevention of Episodic Cluster Headache.

R. Conley, D. Dodick, S. Aurora, 2019, The New England journal of medicine.

Clinical and Functional Outcomes of Patients Who Experience Partial Response to Citalopram: Secondary Analysis of STAR*D

S. Wisniewski, L. Marangell, G. Balasubramani, 2014, Journal of psychiatric practice.

Vagus Nerve Stimulation Therapy in a Patient with Treatment-Resistant Depression: A Case Report of Long-Term Follow-up and Battery End-of-Service

H. Zboyan, James M Martinez, Holly A Zboyan, 2006, CNS Spectrums.

Vagus nerve stimulation: A new tool for treating depression

H. Sackeim, M. George, L. Marangell, 2005 .

Vagus nerve stimulation as a potential option for treatment-resistant depression

L. Marangell, J. Martinez, Shehzad K. Niazi, 2004, Clinical Neuroscience Research.

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder

C. Goldberger, Peng Liu, Qi Zhang, 2015, Drugs in context.

Safety and Tolerability of Edivoxetine for Long-Term Treatment of Major Depressive Disorder in Adult Patients

W. White, C. Goldberger, M. Bangs, 2014 .

A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode

M. Thase, W. Katon, L. Marangell, 2012, International clinical psychopharmacology.

Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain Who Used versus Did Not Use Concomitant Nonsteroidal Anti-Inflammatory Drugs or Acetaminophen: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

Peng Liu, Shuyu Zhang, V. Skljarevski, 2012, Pain research and treatment.

Societal burden of cluster headache in the United States: a descriptive economic analysis

J. Martinez, B. Chu, J. Ford, 2018, Journal of medical economics.

Drug, Healthcare and Patient Safety Dovepress

Qi Zhang, M. Bangs, J. Martinez, 2022 .

A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms

L. Marangell, M. Robinson, J. Martinez, 2011, Current medical research and opinion.